N-(5-(6-Morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide

ID: ALA4790714

PubChem CID: 140322482

Max Phase: Preclinical

Molecular Formula: C24H22N2O4S

Molecular Weight: 434.52

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CC(=O)Nc1ccc2c(c1)Cc1cccc(-c3cc(=O)cc(N4CCOCC4)o3)c1S2

Standard InChI:  InChI=1S/C24H22N2O4S/c1-15(27)25-18-5-6-22-17(12-18)11-16-3-2-4-20(24(16)31-22)21-13-19(28)14-23(30-21)26-7-9-29-10-8-26/h2-6,12-14H,7-11H2,1H3,(H,25,27)

Standard InChI Key:  ZAIGKAZSYXDDBD-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   12.5540   -9.5261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2613   -9.9307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8472   -9.9346    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.5494   -8.7090    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.1255   -6.2613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1302   -7.0785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8374   -7.4831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8421   -8.3003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1353   -8.7129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4280   -8.3083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4234   -7.4911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7120   -7.0824    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    9.7115   -6.2652    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0042   -5.8607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9996   -5.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7063   -4.6309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4136   -5.0396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4182   -5.8568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2974   -6.2733    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2980   -7.0905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5912   -7.5031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8839   -7.0944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8793   -6.2772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5860   -5.8687    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.5958   -8.3203    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7533   -5.0594    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4601   -4.6509    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1674   -5.0554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1720   -5.8726    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4652   -6.2852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7580   -5.8765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  3  2  0
  1  4  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  6 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 13 18  2  0
  5 18  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 19 24  1  0
 21 25  2  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 26 31  1  0
 23 29  1  0
 14 19  1  0
  4  8  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4790714

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 434.52

Molecular Weight (Monoisotopic): 434.1300

AlogP: 4.16

#Rotatable Bonds: 3

Polar Surface Area: 71.78

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: 3.53

CX LogD: 3.53

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.52

Np Likeness Score: -0.84

References

1. Toledo-Sherman L,Breccia P,Cachope R,Bate JR,Angulo-Herrera I,Wishart G,Matthews KL,Martin SL,Cox HC,McAllister G,Penrose SD,Vater H,Esmieu W,Van de Poël A,Van de Bospoort R,Strijbosch A,Lamers M,Leonard P,Jarvis RE,Blackaby W,Barnes K,Eznarriaga M,Dowler S,Smith GD,Fischer DF,Lazari O,Yates D,Rose M,Jang SW,Muñoz-Sanjuan I,Dominguez C.  (2019)  Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.,  62  (6): [PMID:30840447] [10.1021/acs.jmedchem.8b01819]

Source

Source(1):

• Scientific Literature